PharmaShots | Incisive News in 3 Shots

Subscribe Now

Reistone Biopharma

Reistone Biopharma’s Ivarmacitinib Meets its Primary Endpoint in P-III (QUARTZ3) Trial for the Treatment of Atopic Dermatitis

Reistone Biopharma’s Ivarmacitinib Meets its Primary Endpoint in P-III (QUARTZ3) Trial for the Treatment of Atopic Dermatitis

November 16, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us